Scopus Biopharma, Inc. · OTC:SCPS
Scopus Biopharma — STING & TLR-Targeting Therapies Summit 2022
18 slides from Scopus Biopharma's conference presentation, Mar 23, 2022
Slide 1: TLR9 activation and STAT3 inhibition: a bifunctional approach to immuno-oncology
TLR9 activation and STAT3 inhibition: a bifunctional approach to immuno - oncology March 2022 STING & TLR - Targeting Therapies Summit 2022
Slide 2: Investment highlights
Investment highlights 2 Duet’s platform provides a unique approach to treating hematological malignancies and solid tumor cancers Strong IP position Duet has 4 issued patents and 4 submitted PCT applications that cover the technologies that make up Duet’s platform. Bi - functional mode of action Due
Slide 3: Technology portfolio
Technology portfolio 3 The Duet technologies create a powerful portfolio of bi - functional molecules that hold broad potential across multiple tumor types Molecule name CpG - STAT3siRNA (DUET - 01) CpG - STAT3ASO (DUET - 02) CpG - STAT3decoy (DUET - 03) Structure STAT3 mechanism of action Bi - func
Slide 4: Duet pipeline
Duet pipeline 4 Duet’s pipeline of STAT3 inhibitors includes a suite of technologies and several expansion indications in immuno - oncology Candidate Program / indication Discovery / optimization IND enabling Phase 1 Development DUET - 01 B - cell non - Hodgkin lymphoma DUET - 01 + ICI B - cell non
Slide 5: The problem
The problem 5 Tumor cells co - opt the immune system to evade adaptive immunity and promote oncogenesis in the TME Tumors use checkpoints to evade immune response and block activity of cytotoxic T cells and NK cells 2 Tumors recruit T reg and immature myeloid cells to create an immunosuppressive env
Slide 6: STAT3 as an I-O target
STAT3 as an I - O target 6 STAT3 has been implicated in maintaining immunosuppression within the microenvironment of many solid tumors • STAT3 has been shown as key factor in maintenance of immunosuppressive environment found in many solid malignancies, and is activated by many oncogenic pathways •
Slide 7: STAT3 as an I-O target: master regulator of the immune system
STAT3 as an I - O target 7 STAT3 is a master regulator of the immune system and a high - value immuno - oncology target, but requires cell - specific modulation Tumor cell STAT3 • Immune evasion • Proliferation • Angiogenesis • Metastasis STAT3 plays a major role in maintaining immunosuppression in
Slide 8: TLR9 as an I-O target
8 TLR9 activation provokes both innate and adaptive immune responses • Toll like Receptor 9 (TLR9) is an internal cellular receptor in immune cells involved in activation of innate immune responses • Recognizes unmethylated sections of microbial DNA • Synthetic CpG oligonucleotides recognized by rec
Slide 9: The Duet solution
The Duet solution 9 Duet strategy: bi - functional oligonucleotide activates the immune system (TLR9) and turns off immunosuppression (STAT3) Scavenger receptors on the surface of myeloid cells have a high affinity for Duet’s oligos, leading to rapid and specific uptake 1 Duet’s oligos are internali
Slide 10: siRNA for B-cell NHL: DUET-01 complete response in A20 model
siRNA for B - cell NHL 10 DUET - 01 targets TLR9 + immune cells and results in complete response in A20 model of B - cell non - Hodgkin lymphoma Zhang et al. , TLR9 - mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo, Blood (2013) CpG STAT3siRNA DUET - 0
Slide 11: siRNA for B-cell NHL: DUET-01 performs better than ICIs
siRNA for B - cell NHL 11 DUET - 01 performs better than ICIs in A20 model of B - cell NHL , but may have synergistic effect with CPIs at lower dose levels 1 3 5 7 9 11 The day after treatment DUET - 01, injected peritumorally at lower dose levels (10 ug), may have synergistic effect in combination
Slide 12: Phase 1 clinical trial
Phase 1 clinical trial 12 A Phase I study of intratumoral injections of DUET - 01 with local radiation in patients with relapsed/refractory B - cell NHL ELIZABETH BUDDE, MD, PHD Associate Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation at City of Hope P
Slide 13: ASO for prostate cancer: restores T-cell proliferation and activity
ASO for prostate cancer 13 DUET - 02 restores human T - cell proliferation and activity in the prostate tumor microenvironment T - cell proliferation T - cell killing activity CpG STAT3ASO DUET - 02 Moreira et al. , STAT3 inhibition combined with CpG immunostimulation activates antitumor immunity to
Slide 14: ASO for prostate cancer: T-cell mediated rejection in mice
ASO for prostate cancer 14 DUET - 02 induces T - cell mediated rejection of bone - localized and ICI - resistant prostate cancers in mice Ras/Myc - driven (RM9) prostate cancer Ras/Myc-driven tumors (RM9) 5 mg/kg q2d PTEN - deficient (PPS) prostate cancer PD1 and CTLA4 Inhibitors (RM9) Ras/Myc - dri
Slide 15: ASO for head & neck cancer: CD8+ T-cell responses in humanized mice
ASO for head & neck cancer 15 DUET - 02 generates effective CD8 + T - cell immune responses against human HPV - head and neck cancer (HNC) in humanized mice CpG - STAT3ASO (DUET - 02) results in regression of xenotransplanted human head and neck tumors (SCC1) in humanized mice, with evidence of immu
Slide 16: Planned clinical trials
Planned clinical trials 16 Duet is planning two clinical Phase 1 trials to begin in Q1 2023 for Genitourinary and Head & Neck Cancers Genitourinary Cancers Systemic intravenous infusions of DUET - 02 as a monotherapy for treatment of metastatic prostate, kidney, and bladder cancers Head & Neck Cance
Slide 17: Duet leadership team
17 Duet is building a leadership team that has extensive company building and clinical development experience Leadership team ALAN HORSAGER, PHD President, CEO, & Board of Directors MARCIN KORTYLEWSKI, PHD Co - Founder of Olimmune & Senior Scientific Advisor JOHN ROSSI, PHD Professor and Co - Founde
Slide 18: Contact
Contact Alan Horsager, Ph.D. President – Immuno - Oncology, Scopus BioPharma President & CEO, Duet BioTherapeutics horsager@duettx.com
Scopus BioPharma — STING & TLR-Targeting Therapies Summit 2022 on 6ix